Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35249, USA Correspondence to: Rebecca C. Arend, MD. University of Alabama at Birmingham, 619 19 Street South, 176F Room 10250, Birmingham, AL 35249, USA. Email: rarend@uabmc.edu. Provenance: This is an invited article commissioned by the Executive Editor Dr. Zhi-De Hu (Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China). Comment on: Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 2019;154:294-301.